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Thioredoxin structure and mechanism: conformational
changes on oxidation of the active-site sulfhydryls
to a disulfide
The recent high-resolution solution structures of human and Escherichia coli
thioredoxin in their oxidized and reduced states support a catalytic model of
protein disulfide reduction involving binding of a target protein and nucleophilic
attack by the active-site Cys32 thiolate to form a transition state mixed disulfide.
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Thioredoxin is a truly ubiquitous protein, present in all
species from Archebacteria to man. It has a large and
growing number of known functions (reviewed in [1]) in
addition to its role in DNA synthesis by virtue of its act-
ing as a hydrogen donor for the essential enzyme ribonu-
cleotide reductase. In most of its functions, thioredoxin
serves as a general protein disulfide oxido-reductase. It
interacts with a broad range of proteins either for elec-
tron transport in substrate reduction or regulation of
activity via thiol-redox control [1] by a seemingly simple
redox mechanism based on reversible oxidation of two
cysteine thiol groups to a disulfide, accompanied by the
transfer of two electrons and two protons. The net result
is the covalent interconversion of a disulfide and a dithiol.
Protein disulfide reduction by the thioredoxin system is
illustrated in Fig. 1.
The structure of thioredoxin has been the subject of
many investigations since elucidation of the amino acid
sequence of the Escherichia coli protein in 1968 showed it
to comprise 108 amino acid residues [2], including the
now classical active-site sequence, Trp-Cys32-Gly-Pro-
Cys35 [1]. It has been a long-standing goal to observe the
three-dimensional structures of both the oxidized and
reduced forms of thioredoxin. This has recently been
achieved through the publication of high-resolution
Fig. 1. Mechanism of NADPH-dependent protein disulfide
reduction by the thioredoxin system. Thioredoxin reductase (TR)
catalyzes reduction of oxidized thioredoxin (Trx-S2) by NADPH
using FAD and its redox-active disulfide. Reduced thioredoxin
[Trx-(SH)2] then directly reduces the disulfide in the substrate
protein [1]. Using NADPH (100 ItM), TR (0.1 tzM) and Trx-S2(2 p.M) plus a substrate protein, disulfide reduction is measured
spectrophotometrically at 340 nm.
solution structures of both the reduced [Trx-(SH) 2] and
oxidized (Trx-S 2) forms of human [3] and E. coli [4]
thioredoxins. These structures present new opportunities
for understanding the catalytic activity of thioredoxin as a
protein disulfide reductase. They are also of wider interest
in view of the number of proteins with a thioredoxin fold
(see the accompanying article in this issue of Structure [5]
for a more detailed discussion of the thioredoxin fold) and
the increasing functional importance of thiol-redox regu-
lation of protein activity in different biological systems.
Measuring thioredoxin activity
Insulin is a favorite disulfide substrate for assays of thiore-
doxin with an apparent Michaelis-Menten constant (Kid)
in the micromolar range [6,7]. The first evidence for a
local conformational change in thioredoxin on reduction
of the active-site disulfide was a three-fold increase in
tryptophan fluorescence emission [8], now known to
originate from a decreased quenching of Trp28 [4].
Trp28 fluorescence is thus an exceptionally useful probe
for directly measuring rates of thiol-disulfide exchange
reactions with thioredoxin. Trx-(SH) 2 reduces insulin
disulfides at pH 7 with a rate constant of 105 M - s- ,
which is about five orders of magnitude faster than
insulin reduction by dithiothreitol (DTT), a well-known
dithiol reductant [7]. Also, reduction of Trx-S2 by DTT
(103 M-' s - ) is about three orders of magnitude faster
than reduction of insulin disulfides by DTT. As a result,
thioredoxin catalyzes reduction of insulin disulfides by
DTT [7]. In general, thioredoxin will catalyze thiol-
disulfide exchange between one protein dithiol and
another protein disulfide acceptor [1]. Even faster disul-
fide reduction rates (106 M-1 s-1) are observed with the
disulfide in oxidized ribonucleotide reductase which is
involved in electron transfer to the active site [1]. How
can these fast rates with thioredoxin be explained and
what is the nature of the conformational change?
The thioredoxin mechanism based on the structure of Trx-S2
The first three-dimensional structure of any thioredoxin
was obtained by X-ray crystallography in 1975 [9]. E. coli
Trx-S 2 was shown to have its active site disulfide located
on a unique protrusion at the C-terminal end of a
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as determined from the pH dependence, whereas the
other cysteine residue (Cys35) showed a higher pKa value.
This led to a postulated mechanism of action of thiore-
doxin [13] as shown in Fig. 3. The basic concepts of this
mechanism are: firstly, reduced thioredoxin has a
hydrophobic surface area, conserved in the thioredoxin-
glutaredoxin family [14], which binds to a substrate pro-
tein (X in Fig. 3) making a complex; secondly, in the
hydrophobic environment of the complex, the thiolate of
Cys32, acting as a nucleophile, attacks the target protein
to form a covalently linked mixed disulfide transition
state; finally, attack of the now deprotonated thiolate of
Cys35 on the disulfide generates a dithiol in the target
protein and a disulfide in thioredoxin. Conformational
changes in thioredoxin and the target protein occur dur-
ing binding and the subsequent electron-transfer steps.
Fig. 2. Folding of thioredoxin. The secondary structure of thiore-
doxin from coordinates for E. coli Trx-S2 obtained by NMR in
solution [4]. Note that the redox-active disulfide in the active site
(Cys32-Cys35) is located on a protrusion between the strand 2
and the helix ca2. Only the sulfur of Cys32 is exposed to solvent.
[3-strand (32) followed by a long a-helix (a 2). This struc-
ture (see Fig. 2) has since been refined to 1.7 A resolu-
tion [10] revealing details of the know well-known
thioredoxin fold [11] also present in other proteins like
protein disulfide-isomerase which has two thioredoxin
domains and makes, rather than breaks, disulfides [11].
Despite the successful X-ray work with oxidized thio-
redoxin the structure of the reduced form remained elu-
sive. This was because crystals of E. coli thioredoxin were
only obtained in the presence of Cu2 + ions [12] which act
to cross-link two molecules by coordination at Serl, Asp2
and AsplO [9,10]. This requirement for Cu2 + precludes
crystallization of reduced thioredoxin because Cu 2+ is an
oxidizing substrate [6]. However, chemical modification
showed that only Cys32, the N-terminal active-site cys-
teine residue, was alkylated by iodoacetate in the native
protein at pH 7, and that the apparent pK a value was 6.7
This protein-protein binding mechanism may explain
how thioredoxin can reduce a disulfide in a protein
which appears sterically inaccessible to a small molecule
like DTT. Activation of malate dehydrogenase from
spinach chloroplasts with thioredoxin m (one of several
chloroplast thioredoxins) is a good example [15]. It is also
an example of a specific thioredoxin-dependent reaction
that mediates light-driven regulation of photosynthetic
enzymes by ferredoxin and a specific reductase.
The high-resolution NMR work on thioredoxin in solu-
tion, initially focused on the reduced form of the human
[16] and E. coli [17] proteins. Cloning of human thio-
redoxin resulted from a novel functional role of this pro-
tein as a secreted cytokine [18], isolated from either
conditioned medium of human T-lymphotropic virus
type I transformed T cells or from Epstein-Barr virus
transformed B cells [19,20]. Like other mammalian thio-
redoxins [1], the human protein contains additional
structural cysteine residues with sulfhydryl groups [11];
one of these, Cys73, is located on the surface close to the
active site and in an equivalent position to Gly74 in
E. coli thioredoxin [3,4]. Oxidation of these structural
sulfhydryl groups inactivates the mammalian thioredoxins
causing them to aggregate and form multimers, a process
that has been suggested to autoregulate activity [1,21]. To
analyze the human oxidized thioredoxin [3], the triple
Cys---Ala mutant protein C62A, C69A, C73A was con-
structed [22]. This had equivalent activity to the wild-
type thioredoxin in the DTT-coupled insulin disulfide
Fig. 3. Proposed mechanism of thiore-
doxin-catalyzed protein disulfide reduc-
tion [1,13]. Reduced thioredoxin
[Trx-(SH)2 ] binds to a target protein via
its hydrophobic surface area. Nucleo-
philic attack by the thiolate of Cys32
results in formation of a transient mixed
disulfide, which is followed by a
nucleophilic attack of the deprotonated
Cys35 generating Trx-S2 and the
reduced protein. Note that conforma-
tional changes in thioredoxin (and the
target protein) occur during the reaction.
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reduction assays [21]. It should be noted that the human
thioredoxin analyzed also contains the substitution
Met74-->Thr [18,19,22]. Analysis of oxidized E. coli
thioredoxin [3] was straightforward.
Mechanistic implications of conformational changes between
reduced and oxidized thioredoxin
The papers on human and E. coli thioredoxins [3,4]
contain a good deal of detailed information about the
structures that falls outside the scope of this minireview.
Here, I will focus on the essence of the conformational
change and, in particular, its mechanistic implications.
Despite only 25% sequence identity between E. coli and
human thioredoxins, the active site Trp-Cys-Gly-
Pro-Cys motif and other critical residues such as Pro76
and Gly92 of the E. coli protein are conserved in the
human structure [3,4,11]. The major conclusions are
discussed below.
For E. coli thioredoxin, the structures of the oxidized and
reduced forms are extremely similar. Their backbones are
essentially identical except for slight differences in the
active site including Cys32 and Cys35. The side chain of
Cys32 is tilted towards the solution in the reduced form
to accommodate the increase in sulfur-sulfur distance
upon formation of two sulfhydryl groups. Changes are
seen in other side chains and in the hydrogen-bonding
pattern [4]. Fig. 4 illustrates the surfaces of oxidized and
reduced thioredoxin as space-filling models. Clearly, only
the sulfur of Cys32 is exposed to solvent. The low pKa
value of Cys32 [13,23,24] is suggested to arise from the
partial positive charge from the a-helix dipole moment
of helix xa2 [25].
What then, is the difference between the oxidized and
reduced states illustrated in Fig. 4? A target protein with
a disulfide bond should bind well to the surface of
Trx-(SH)2, but not to Trx-S2. Such complexes have not
yet been studied. However, a striking example of a true
difference in recognition is observed with phage T7
DNA polymerase. This enzyme, widely used for DNA
sequencing, consists of a 1:1 complex of Trx-(SH)2 and
the 80 kDa phage T7 gene 5 protein [26]. The complex
has a dissociation constant of -5 nM and thioredoxin
confers high processivity on the enzyme. No redox func-
tion is required for processivity and active site
Cys32/35-4Ser double mutants of thioredoxin are also
functional [26]. In contrast, no activity or binding of
Trx-S2 to the gene 5 protein is observed (the binding
affinity is reduced by at least four orders of magnitude;
[26] and A Holmgren, unpublished data). The
hydrophobic surface area shown in Fig. 4 is clearly
involved in determining target specificity because a
mutant thioredoxin in which Gly92 (colored magenta in
Fig. 4) is substituted by an aspartate residue, thereby
introducing a negative charge, lacks all gene 5 binding
activity [26]. Interestingly, the Gly92-Asp variant
obtained from an E. coli mutant with a T7 negative phe-
notype [27] was the first natural mutant of thioredoxin
to be isolated. However, the Gly92--Asp thioredoxin
Fig. 4. Molecular models of the active-site surface of E. coli
thioredoxin in (a) the oxidized state and (b) the reduced state.
The view in this figure is from the back (180 ° rotation) of the
structure presented in Fig. 2. The sulfur of Cys32 (yellow) and
the conserved residues Trp31, Pro34 and Pro76 are indicated.
All atoms in Gly92 are shown colored magenta.
mutant retains -10% of wild-type activity in assays with
thioredoxin reductase and insulin (displaying both a
lower Vm1ax and a higher K, if assayed by the method
shown in Fig. 1 [27]).
The topic of substrate recognition by thioredoxin is
addressed in a paper in this issue of Structure [28] which
presents the structure of a mixed disulfide transition state
intermediate complex between human thioredoxin and
a peptide fragment from one of its target proteins, the
transcription factor NFKB.
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It remains to be determined whether the functional dif-
ferences between the two oxidation states, which have
such similar active-site surfaces (see Fig. 4), arise from
local conformational flexibility in and around the disul-
fide loop [29]. Higher mobility is observed in the
reduced form, in the microsecond to millisecond
timescale, consistent with conformational subsets of
structures in the reduced form that may be important for
binding target proteins. The exact nature of the structural
flexibility remains to be determined.
The structures of the oxidized and reduced C62A, C69A,
C73A, M74T human thioredoxin are also very similar
(with a backbone atomic root mean square difference of
-0.9 A) and the packing of the side chains within the
protein core is almost identical [3]. However, subtle dif-
ferences are observed in the local conformation of the
active site and surrounding regions. These can be attrib-
uted to a slight shortening of the C-Ca distance by
-0.1 A between Cys32 and Cys35 upon formation of the
disulfide bond and a change in the X1 angle of Cys35
from -50.9 ° in the reduced state to -39.1 ° in the oxidized
state [3]. A small change in the position of the Trp31 side
chain is also observed. The changes in the active site are
propagated to the neighboring helices ao2 and a 4, whose
orientations with respect to the underlying [3-sheet are
slightly different in the oxidized and reduced forms [3].
This includes the loops (74-76 and 90-92) that make up
the active-site surface (see Figs 2 and 4 for orientation).
The cleft between the active site and the two opposing
loops is increased by -10% in the oxidized state relative to
the reduced state. Apart from movement of the helices,
another clear difference between the results obtained with
E. coli thioredoxin and human thioredoxin concerns the
sulfur-sulfur distance in the reduced state, which is 3.1 A
in human thioredoxin [3] but 3.8 A in the E. coli protein
[4]. A hydrogen bond between the Cys35 amide proton
and the Cys32 S, which is present in oxidized human
thioredoxin, is retained in the reduced state and may
explain the low pKa value (6.3) measured for Cys32 in
human thioredoxin [30].
In summary, the active-site surfaces of human and E. coli
thioredoxin are highly conserved. The changes observed
upon oxido-reduction are subtle and local and require
the full might of present-day multidimensional NMR
techniques to be detected. However, there do appear to
be genuine, albeit small, differences between the human
and E. coli proteins. The kinetics of the redox activity
with insulin are very similar for both thioredoxins sug-
gesting that nature has solved the mechanism of thio-
redoxin in slightly different ways. An alternative
explanation is that the mutations C62A, C69A, C73A
and M73T cause changes in the native structure. Clearly,
further studies detailing the binding interactions of pro-
teins with thioredoxin will be of great interest. It should
also be noted that glutaredoxin has a binding site for glu-
tathione [31] and uses this molecule either for reduction
of the active-site disulfide or in substrate recognition.
Apparently, the active-site surface in thioredoxin is
designed to fit many proteins. Thioredoxin thus uses a
chaperone-like mechanism of conformational changes to
bind a diverse group of proteins and fast thiol-disulfide
exchange chemistry in a hydrophobic environment [32]
to promote high rates of disulfide reduction.
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